Angiotensin II for Septic Shock Treatment

• Status: Suspended
• Trial end date: 2019-08-15
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the effect of angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Angiotensin II; Angiotensinogen; Giapreza; Norepinephrine

Criteria

Inclusion Criteria:

• Septic shock patients.

• Aged above 18 years.

• With cardiac index > 2.4 L/min/BSA 1.73 m2.

• On high dose vasopressors (defined as norepinephrine infusion above 0.1 mcg/Kg/min)

Exclusion Criteria:

• Acute coronary syndrome.

• Impaired cardiac contractility

• Bronchospasm.

• Major burns

• Liver failure.

• Active bleeding.